E-RCT: My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 Diabetes

Sponsor
University of Illinois at Chicago (Other)
Overall Status
Recruiting
CT.gov ID
NCT05208164
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
100
1
2
19
5.3

Study Details

Study Description

Brief Summary

The proposed research and training will allow Dr. Alana Biggers to obtain critical research skills and study a mindfulness meditation program designed to improve sleep and reduce stress in African-American adults with diabetes. If effective, this program may reduce the risk of cardiovascular disease among African-Americans with type 2 diabetes who are at high risk of cardiovascular disease.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfunlness Meditation
N/A

Detailed Description

African-Americans have disproportionate rates of cardiovascular disease (CVD) in the US. African-Americans with type 2 diabetes (T2DM) have twice the risk than non-Hispanic whites for developing CVD. Poorer sleep and greater chronic psychological stress may contribute to this additional risk. Consequently, African-Americans have worse glycemic control among those with diabetes and higher CVD risk. One promising approach to improving CVD risk in African-Americans is mindfulness meditation (MM). MM can potentially reduce cardiovascular risk through attention control, emotional regulation, and self-awareness. The overall purpose of this K01 training grant is for Dr. Alana Biggers to obtain research training and develop skills needed to become an independent investigator, and use those skills to adapt and evaluate an established MM curriculum. The specific aims are to: (1) adapt and refine an established MM curriculum for African-Americans with T2DM and incorporate text messaging; (2) conduct an 8-week, pilot randomized, controlled trial of the adapted curriculum with 68 African-Americans with T2DM; and (3) explore the impact of the intervention on cardiometabolic risk factors (blood pressure, glycosylated hemoglobin, and lipid profile) and inflammatory biomarkers (C-reactive protein, interleukin-6, and tumor necrosis factor α). Primary outcomes will include sleep quality and perceived stress evaluated at baseline, 8, and 16 weeks. The proposed research design consists of a pilot study, utilizes mixed-methods research, and involves both primary data collection and analysis. This K01 training grant will provide Dr. Biggers career-building activities to further develop skills and a knowledge base in quantitative and qualitative methodology, health disparities research, and mobile health (mHealth)/behavioral health strategies in minority populations. With the guidance of an interdisciplinary mentorship team and institutional support, Dr. Biggers will receive the necessary assistance and training to work toward her long-term career goal of being an independent researcher with expertise in health disparities, mixed-methods, and mHealth behavioral research.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Group A will be assigned as the intervention group and Group B will be assigned as the usual care group. During the pilot RCT, Group A will run in parallel with Group B.Group A will be assigned as the intervention group and Group B will be assigned as the usual care group. During the pilot RCT, Group A will run in parallel with Group B.
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
My ESSENCE - Mindfulness to Reduce Stress, Improve SIeep, and Reduce Cardiovascular Risk in African-Americans With Type 2 Diabetes
Actual Study Start Date :
May 15, 2022
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Dec 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness Meditation Classes

8 mindfulness classes: Participants will engage in 8 two-hour mind and body practice classes over 8 weeks in-person or online (during the pandemic). You will receive compensation for your participation and a yoga mat. You will need to wear comfortable clothing. These sessions can be done sitting in chair, sitting on the floor, or standing. Text messaging., in between classes you will receive text messages to encourage mind and body practices at home. Text messaging may appear as the following: 1.Do you have time to meditate right now? Yes or No. 2.Did you practice your mindfulness today? Yes or no. 3.Remember to wind down this evening and do not drink any caffeinated beverages 4 hours before bed.

Behavioral: Mindfunlness Meditation
Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms

No Intervention: Usual Care

Outcome Measures

Primary Outcome Measures

  1. Sleep Quality [Change from baseline at 8 and 16 weeks.]

    Will use Pittsburgh Sleep Quality Index (PSQI). PSQI has a minimum score of 0 (better) and maximum of 21 (worse). Score > 5 is considered poor quality sleep.

  2. Perceived Stress [Change from baseline at 8 and 16 weeks.]

    Will use Perceived Stress Scale. Scale has a minimum value of 0, and maximum value of 40. Scores from 0-13 are considered low stress, 14-26 are moderate, and 27-40 are high perceived stress.

  3. Sleep Disturbances [Change from baseline at 8 and 16 weeks]

    Will use Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form 8b. Scores are reported as T-scores, with 28.9 being the minimum value, and 76.5 being the maximum. Higher scores indicate greater sleep disturbances.

  4. Sleep Impairment [Change from baseline at 8 and 16 weeks]

    Will use Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment Short Form 8a.Scores are reported as T-scores, with 30.0 being the minimum value, and 80.1 being the maximum. Higher scores indicate greater sleep impairment.

Secondary Outcome Measures

  1. Cardiovascular Risk [Change from baseline at 8 weeks]

    Fasting lipid profile (total cholesterol, HDL, LDL and triglycerides) and blood pressure will be combined to estimate 10 year cardiovascular risk using the American College of Cardiology Atherosclerotic Cardiovascular Disease (ACC ASCVD) Risk Estimator Plus Calculator.

  2. Hemoglobin A1c [Change from baseline at 8 weeks.]

    Will use HbgA1c as a measure for determining cardiovascular risk.

  3. Inflammatory Markers [Change from baseline at 8 and 16 weeks]

    IL-6, CRP, TNF-alpha

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Inclusion Criteria

  • Self-identifies as African American or Black

  • Diagnosis of type 2 diabetes

  • Valid address in greater Chicagoland area

  • Mobile phone with unlimited text-messaging

  • Mobile device (smartphone, tablet, or computer) with the ability to connect to the internet if remote online delivery

  • Availability to participate in mindfulness class either in-person or online

  • Age 21-75

Exclusion Criteria

  • Untreated obstructive sleep apnea (OSA)

  • Severe insomnia, narcolepsy, or REM sleep related disorder

  • Major cognitive impairments or psychiatric disorder

  • Alcohol or drug abuse

  • Limited English proficiency

  • Inability to send/receive text messages

  • Currently engaging in mindfulness practice

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Illinois at Chicago Chicago Illinois United States 606012

Sponsors and Collaborators

  • University of Illinois at Chicago
  • National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Principal Investigator: Alana Biggers, University of Illinois at Chicago

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alana Biggers, Primary Investigator, University of Illinois at Chicago
ClinicalTrials.gov Identifier:
NCT05208164
Other Study ID Numbers:
  • 2019-1433
  • 1K01HL149775-01
First Posted:
Jan 26, 2022
Last Update Posted:
May 25, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 25, 2022